OMNIAB, INC. Impairment of Intangible Assets, Finite-lived
OMNIAB, INC. (OABI) reported Impairment of Intangible Assets, Finite-lived of $2.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2026-08-06
- OMNIAB, INC. impairment of intangible assets, finite-lived for the quarter ending 2026-06-30 was $0.00.
- OMNIAB, INC. impairment of intangible assets, finite-lived for the quarter ending 2026-03-31 was $2.90M.
- OMNIAB, INC. impairment of intangible assets, finite-lived for the quarter ending 2025-12-31 was $0.00.
- OMNIAB, INC. impairment of intangible assets, finite-lived for the quarter ending 2025-09-30 was $0.00.
- OMNIAB, INC. impairment of intangible assets, finite-lived for fiscal 2025 was $0.00.
- OMNIAB, INC. impairment of intangible assets, finite-lived for fiscal 2023 was $0.00.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.90M 10-Q · filed 2026-08-06 | $2.90M derived: sum of 3 quarters · filed 2026-08-06 | $2.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.90M 10-Q · filed 2026-05-07 | $2.90M derived: sum of 2 quarters · filed 2026-05-07 | $2.90M derived: sum of 3 quarters · filed 2026-05-07 | $2.90M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $0.00 derived: sum of 2 quarters · filed 2026-03-04 | $0.00 derived: sum of 3 quarters · filed 2026-03-04 | $0.00 10-K · filed 2026-03-04 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 | $0.00 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | |||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.20M derived: sum of 2 quarters · filed 2024-11-12 | $1.20M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $1.20M 10-Q · filed 2024-08-08 | $1.20M 10-Q · filed 2024-08-08 | ||
| 2023-12-31 | $0.00 10-K · filed 2025-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |